Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,130 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06474611 | Evaluation of a Patient 'nudge' on Engagement in Lung Cancer Screening | completed | N/A | 894 | Kaiser PermanenteOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06438367 | TGRX-326 Pharmacokinetic Mass Balance | completed | Phase 1 | 6 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05000684 |
| Study of JS004 Combined With Toripalimab for Advanced Lung Cancer |
| completed |
| Phase 1 / Phase 2 |
| 67 |
| Shanghai Junshi Bioscience Co., Ltd.OTHER |
| 1 |
| Feb 20, 2025 |
| clinicaltrials |
| NCT02597946 | Afatinib in NSCLC With HER2 Mutation | completed | Phase 2 | 18 | Boehringer IngelheimINDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT03088813 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer(RESILIENT) | completed | Phase 3 | 491 | IpsenINDUSTRY | 18 | Feb 19, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04023812 | Stage III NSCLC RWE in Chinese Patients | completed | — | 500 | AstraZenecaINDUSTRY | 1 | Feb 18, 2025 | clinicaltrials |
| NCT05227261 | Early Detection of Five Common Cancers Using the ctDNA Analysing Test(K-DETEK) | completed | — | 9,057 | Gene SolutionsINDUSTRY | 1 | Feb 18, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT00708448 | Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients | completed | Phase 1 | 26 | University of UtahOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT00984321 | A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer | completed | N/A | 107 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03669523 | Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)(DENIVOS) | completed | Phase 2 | 82 | Centre Hospitalier Annecy GenevoisOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03992664 | Education Intervention in Patients with Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment. | completed | N/A | 40 | Cyprus University of TechnologyOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT01346540 | A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. | completed | Phase 1 | 16 | Boehringer IngelheimINDUSTRY | 4 | Feb 12, 2025 | clinicaltrials |
| NCT05795959 | Ensuring Precision-Medicine Delivery for Veterans With Lung Cancer | completed | N/A | 46 | Stanford UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02300298 | Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy | completed | Phase 1 | 10 | Boehringer IngelheimINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT03414814 | Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation | completed | Phase 2 | 15 | Seoul National University HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02733159 | Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2(PePS2) | completed | Phase 2 | 62 | University of BirminghamOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03358875 | Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)(RATIONALE-303) | completed | Phase 3 | 805 | BeiGeneINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT01828112 | LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | completed | Phase 3 | 231 | Novartis PharmaceuticalsINDUSTRY | 20 | Feb 7, 2025 | clinicaltrials |
| NCT02349412 | Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers | completed | Phase 3 | 405 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03532880 | A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer | completed | Phase 1 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05021328 | Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC | completed | Phase 1 | 13 | Hubei Cancer HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04263051 | Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer(Optim-UCPVax) | completed | Phase 2 | 60 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03663205 | A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer | completed | Phase 3 | 334 | BeiGeneINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT04564079 | An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network | completed | — | 100 | Exactis InnovationOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | completed | Phase 3 | 1,214 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 42 | Jan 31, 2025 | clinicaltrials |
| NCT03207594 | Improving Evidence-Based Care for Cancer Patients | completed | — | 128 | Medical University of South CarolinaOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT04588064 | 18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma | completed | N/A | 63 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05937425 | The Effect of Nurse Navigation Program on Lung Cancer Patients([LungCaNN]) | completed | N/A | 84 | Akdeniz UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06068842 | A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer(METRIX) | completed | — | 579 | AbbVieINDUSTRY | 12 | Jan 29, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT02841579 | Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M(AZENT) | completed | Phase 2 | 22 | MedSIROTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04954885 | Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity | completed | — | 2 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03285763 | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)(TAIL) | completed | Phase 4 | 619 | Hoffmann-La RocheINDUSTRY | 24 | Jan 23, 2025 | clinicaltrials |
| NCT06789224 | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device(REMOVE) | completed | N/A | 136 | Lindis Bloodcare GmbHINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03667716 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | completed | Phase 1 | 121 | Compugen LtdINDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT05309629 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 40 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT01828099 | LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer | completed | Phase 3 | 376 | Novartis PharmaceuticalsINDUSTRY | 29 | Jan 16, 2025 | clinicaltrials |
| NCT04012606 | Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 3 | 442 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | completed | Phase 1 / Phase 2 | 132 | BioAtla, Inc.INDUSTRY | 6 | Jan 15, 2025 | clinicaltrials |
| NCT03509012 | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors(CLOVER) | completed | Phase 1 | 105 | AstraZenecaINDUSTRY | 5 | Jan 14, 2025 | clinicaltrials |
| NCT01014286 | Lung Cancer Mutation Consortium Protocol | completed | — | 1,100 | University of Colorado, DenverOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04249362 | Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy(DUART) | completed | Phase 2 | 102 | AstraZenecaINDUSTRY | 6 | Jan 10, 2025 | clinicaltrials |
| NCT02818426 | Universal Cancer Peptide-based Vaccination in Metastatic NSCLC(UCPVax) | completed | Phase 1 / Phase 2 | 82 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT03262779 | Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. | completed | Phase 2 | 20 | Yale UniversityOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT03982459 | National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC | completed | N/A | 76 | University of California, San FranciscoOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT00418886 | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) | completed | Phase 3 | 698 | Genzyme, a Sanofi CompanyINDUSTRY | 21 | Dec 31, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Feb 25, 2025source: clinicaltrials